Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial

Lipids in Health and Disease

Jan P Schuchardt¹  Andreas Hahn¹  Thomas Scheper²  Kai-Oliver Mutz²  Frank Stahl²  Simone Schmidt¹ 

[1] Institute of Food Science and Human Nutrition, Leibniz University of Hannover, Am Kleinen Felde 30, 30167, Hannover, Germany;Institute of Technical Chemistry, Leibniz University of Hannover, Callinstr. 5, 30167, Hannover, Germany

关键词: Omega-3 index;    Omega-3 fatty acids;    Genome microarrays;    Gene regulation;    Cardiovascular disease;    Pathway analysis;    Hypertriglyceridemia;    Dyslipidemia;    Lipid metabolism;   

Others  :  1160226
DOI  :  10.1186/1476-511X-11-105

 received in 2012-04-04, accepted in 2012-08-19,  发布年份 2012

【 摘 要 】

Background

Epidemiological studies have suggested the benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on cardiovascular health, but only limited data are available describing n-3 PUFA regulated pathways in humans. The aim of this study was to investigate the effects of n-3 PUFA administration on whole genome expression profiles in the blood of normo- and dyslipidemic subjects.

Methods

Differentially expressed genes were detected after four hours, one week and twelve weeks of supplementation with either fish oil (FO) or corn oil in normo- and dyslipidemic men using whole genome microarrays.

Results

Independent of the oil, a significantly higher number of genes was regulated in dyslipidemic subjects compared to normolipidemic subjects. Pathway analyses discovered metabolisms dominantly affected by FO after twelve weeks of supplementation, including the lipid metabolism, immune system and cardiovascular diseases. Several pro-inflammatory genes, in particular, were down-regulated in dyslipidemic subjects, indicating the immune-modulatory and anti-inflammatory capability of FO and its bioactive FAs, eicosapentaenoic acid and docosahexaenoic acid.

Conclusions

This is the first study showing significant differences in gene expression profiles between normo- and dyslipidemic men after FO supplementation. Further studies need to clarify the exact role of n-3 PUFAs in pathways and metabolisms which were identified as being regulated after FO supplementation in this study.

Trial registration

ClinicalTrials.gov (ID: NCT01089231)

【 授权许可】

   
2012 Schmidt et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, Abbott RD, Evans RW, Rodriguez BL, Okamura T, Sutton-Tyrrell K, Nakamura Y, Masaki K, Edmundowicz D, Kashiwagi A, Willcox BJ, Takamiya T, Mitsunami K, Seto TB, Murata K, White RL, Kuller LH: Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008, 6:417-424.
• [2]Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, Harada K, Kumagai S, Kunimura A, Shinbo Y, Kitagawa K, Ishii H, Murohara T: Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis 2011, 1:110-116.
• [3]Sudheendran S, Chang CC, Deckelbaum RJ: N-3 vs. saturated fatty acids: effects on the arterial wall. Prostaglandins Leukot Essent Fatty Acids 2010, 82(4-6):205-209.
• [4]Harris WS: Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989, 6:785-807.
• [5]Musa-Veloso K, Binns MA, Kocenas AC, Poon T, Elliot JA, Rice H, Oppedal-Olsen H, Lloyd H, Lemke S: Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev 2010, 3:155-167.
• [6]Tremoli E, Eligini S, Colli S, Maderna P, Risè P, Pazzucconi F, Marangoni F, Sirtori CR, Galli C: n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes. Arterioscler Thromb 1994, 10:1600-1608.
• [7]Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 1:19-30.
• [8]Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM: Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother 2008, 7:1237-1248.
• [9]Adkins Y, Kelley DS: Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 2010, 9:781-792.
• [10]Cottin SC, Sanders TA, Hall WL: The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011, 2:215-231.
• [11]Massaro M, Scoditti E, Carluccio MA, de Caterina R: Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 2008, 79(3–5):109-115.
• [12]Mozaffarian D, Wu JHY: Omega-3 Fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 20:2047-2067.
• [13]Siddiqui RA, Harvey KA, Ruzmetov N, Miller SJ, Zaloga GP: n-3 fatty acids prevent whereas trans-fatty acids induce vascular inflammation and sudden cardiac death. Br J Nutr 2009, 12:1811-1819.
• [14]Jump DB: N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 2008, 3:242-247.
• [15]Nakamura MT, Cheon Y, Li Y, Nara TY: Mechanisms of regulation of gene expression by fatty acids. Lipids 2004, 11:1077-1083.
• [16]Bouwens M, van de Rest O, Dellschaft N, Bromhaar MG, de Groot LCPGM, Geleijnse JM, Müller M, Afman LA: Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009, 2:415-424.
• [17]Gorjão R, Verlengia R, de Lima TM, Soriano FG, Boaventura MFC, Kanunfre CC, Peres CM, Sampaio SC, Otton R, Folador A, Martins EF, Curi TCP, Portiolli EP, Newsholme P, Curi R: Effect of docosahexaenoic acid-rich fish oil supplementation on human leukocyte function. Clin Nutr 2006, 6:923-938.
• [18]Esteve E, Ricart W, Fernández-Real JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005, 1:16-31.
• [19]Harris WS, von Schacky C: The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 2004, 1:212-220.
• [20]Bouwens M, Grootte Bromhaar M, Jansen J, Müller M, Afman LA: Postprandial dietary lipid-specific effects on human peripheral blood mononuclear cell gene expression profiles. Am J Clin Nutr 2010, 1:208-217.
• [21]Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL: A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 2006, 5:653-664.
• [22]Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, Brown PO: Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003, 4:1896-1901.
• [23]Kerr MK, Churchill GA: Experimental design for gene expression microarrays. Biostatistics 2001, 2:183-201.
• [24]Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Edgar R: NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res 2007, 35(Database issue):D760-D765.
• [25]The KEGG PATHWAY Databasehttp://www.genome.jp/kegg/pathway.html webcite
• [26]Harris WS: The omega-3 index: clinical utility for therapeutic intervention. Curr Cardiol Rep 2010, 6:503-508.
• [27]Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002, 4:275-280.
• [28]Lundman P, Eriksson MJ, Silveira A, Hansson L, Pernow J, Ericsson C, Hamsten A, Tornvall P: Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1). Am J Cardiol 2003, 9:1128-1131.
• [29]Vartanian K, Slottke R, Johnstone T, Casale A, Planck SR, Choi D, Smith JR, Rosenbaum JT, Harrington CA: Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. BMC Genomics 2009, 10:2. BioMed Central Full Text
• [30]Kang JX, Weylandt KH: Modulation of inflammatory cytokines by omega-3 fatty acids. Subcell Biochem 2008, 49:133-143.
• [31]Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD: Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 2012, 34:151-165.
• [32]Vanschoonbeek K, Feijge MAH, Paquay M, Rosing J, Saris W, Kluft C, Giesen PLA, de Maat MPM, Heemskerk JWM: Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 2004, 9:1734-1740.
• [33]Tai CC, Ding ST: N-3 polyunsaturated fatty acids regulate lipid metabolism through several inflammation mediators: mechanisms and implications for obesity prevention. J Nutr Biochem 2010, 5:357-363.
• [34]Ide T, Kobayashi H, Ashakumary L, Rouyer IA, Takahashi Y, Aoyama T, Hashimoto T, Mizugaki M: Comparative effects of perilla and fish oils on the activity and gene expression of fatty acid oxidation enzymes in rat liver. Biochim Biophys Acta 2000, 1:23-35.
• [35]Murakami M, Yoshihara K, Shimbara S, Lambeau G, Singer A, Gelb MH, Sawada M, Inagaki N, Nagai H, Kudo I: Arachidonate release and eicosanoid generation by group IIE phospholipase A(2). Biochem Biophys Res Commun 2002, 3:689-696.
• [36]Wilkinson T, Aukema HM, Thomas LM, Holub BJ: Marked enrichment of the alkenylacyl subclass of plasma ethanolamine glycerophospholipid with eicosapentaenoic acid in human subjects consuming a fish oil concentrate. Lipids 1996, 31(Suppl 1):211-215.
• [37]Skwarek M, Bilińska ZT, Mazurkiewicz Ł, Grzybowski J, Kruk M, Kurjata P, Piotrowski W, Ruzyłło W: Significance of dyslipidaemia in patients with heart failure of unexplained aetiology. Kardiol Pol 2008, 5:515-522.
• [38]Campian ME, Verberne HJ, Hardziyenka M, de Groot EAA, van Moerkerken AF, van Eck-Smit BLF, Tan HL: Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Nucl Med Mol Imaging 2010, 11:2079-2085.
• [39]Cihakova D, Rose NR: Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008, 99:95-114.
• [40]Smith CE, Freeman LM, Rush JE, Cunningham SM, Biourge V: Omega-3 fatty acids in Boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Intern Med 2007, 2:265-273.
• [41]Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L: Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011, 7:870-879.
• [42]Kendziorski C, Irizarry RA, Chen K, Haag JD, Gould MN: On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA 2005, 12:4252-4257.